Obermatt
See Similar Stocks →

Janux Therapeutics

NMQ:JANX · US47103J1051
BiotechnologySmall

360

41
EV / EBIT100
Price / Owner Earnings61
Cash yield1
Price/Sales29
Price/Book76
Return on Capital66
Cash Return on Capital76
Return on Equity75
Profit margins23
Accruals46
Owner Earnings Margin11
Sales growth95
Profit growth44
Reinvestment47
Price momentum6
Debt load65
Refinancing50
Debt Payback1
Liquidity8
Analyst ratings21
Opinion Changes50
Price Target Upside82
Market mood91
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Janux Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2017
Employees102
Websitejanuxrx.com
ISINUS47103J1051
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
ImmunologyOncologyHealth DiagnosticsPharmaceuticalTherapeutics

Description

Janux Therapeutics, Inc. (Janux Therapeutics), an clinical-stage biopharmaceutical company. The company develops a broad pipeline of novel immunotherapies by applying its proprietary technologies to Tumor Activated T Cell Engager (TRACTr), Tumor Act…

Analysis

Middle-of-the-road

Janux Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value. Analysts lean positive.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
71
2026

All-time high

71

Jun 2026

All-time low

25

Mar 2026

Average rank

48

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
29
—
—
—
Price/Earnings
68
—
—
—
Price/Book
76
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
77
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Janux Therapeutics with its peers
Bicara Therapeutics
NMQ:BCAX
43
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Coherus Oncology
NMQ:CHRS
72
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Exelixis
NSQ:EXEL
96
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Castle Biosciences
NMQ:CSTL
10
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
CytomX Therapeutics
NSQ:CTMX
8
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kyverna Therapeutics
NSQ:KYTX
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →